Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94107-1739, USA.
J Nucl Med. 2011 Jul;52(7):1068-72. doi: 10.2967/jnumed.110.085944. Epub 2011 Jun 16.
We have developed a practice procedure for prostate lymphoscintigraphy using SPECT/CT and filtered (99m)Tc-sulfur nanocolloid, as an alternative to the proprietary product (99m)Tc-Nanocoll, which is not approved in the United States.
Ten patients were enrolled for this study, and all received radiotracer prepared using a 100-nm membrane filter at a commercial radiopharmacy. Whole-body scans and SPECT/CT studies were performed within 1.5-3 h after the radiotracer had been administered directly into 6 locations of the prostate gland under transrectal ultrasound guidance. The radiation dose was estimated from the first 3 patients. Lymphatic drainage mapping was performed, and lymph nodes were identified.
The estimated radiation dose ranged from 3.9 to 5.2 mSv/MBq. The locations of lymph nodes draining the prostate gland were similar to those found using the proprietary product.
When the proprietary radiolabeled nanocolloid indicated for lymphoscintigraphy is not available, prostate lymph node mapping and identification are still feasible using filtered (99m)Tc-sulfur nanocolloid.
我们开发了一种使用 SPECT/CT 和过滤的 (99m)Tc-硫纳米胶体进行前列腺淋巴闪烁显像的实践程序，作为替代在美国未获得批准的专有产品 (99m)Tc-Nanocoll 的方法。
本研究纳入了 10 名患者，所有患者均在商业放射性药物制备中心使用 100nm 膜过滤器制备示踪剂。在经直肠超声引导下将示踪剂直接注入前列腺的 6 个部位后 1.5-3 小时内进行全身扫描和 SPECT/CT 研究。从前 3 名患者估算了辐射剂量。进行了淋巴引流图绘制，并识别了淋巴结。
估计的辐射剂量范围为 3.9 至 5.2 mSv/MBq。引流前列腺的淋巴结的位置与使用专有产品时发现的位置相似。
当无法获得用于淋巴闪烁显像的专有放射性标记纳米胶体时，使用过滤的 (99m)Tc-硫纳米胶体仍然可以进行前列腺淋巴结定位和识别。
